CD95 ligand expression in dedifferentiated breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• CD95 ligand (CD95L) expression is noted in various cancers.
• The CD95 system (ligand and receptor) plays a role in apoptosis.
• Understanding CD95 system dynamics in breast cancer is crucial.

Purpose of the Study:

• To investigate the expression patterns of CD95 ligand (CD95L) and CD95 receptor in non-malignant and malignant breast tissues.
• To correlate CD95L and CD95 expression with breast tumor histopathological grading.
• To explore the functional implications of CD95L/CD95 interactions in breast cancer progression and invasion.

Main Methods:

• Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for mRNA expression analysis.
• Immunofluorescence for protein expression determination.
• Functional assays involving co-culture of target cells with breast cancer tissue sections and CD95L blocking.

Main Results:

• CD95L mRNA levels positively correlated with tumor grade, increasing significantly with higher grades.
• CD95 mRNA levels inversely correlated with tumor grade, being higher in benign tissues and lower in high-grade carcinomas.
• Tumor-infiltrating lymphocytes and stromal cells near CD95L-expressing tumors underwent apoptosis, which could be blocked by CD95-Fc.
• Target cells cultured on breast cancer sections underwent apoptosis, preventable by CD95L blockade.

Conclusions:

• Breast cancer dedifferentiation is associated with inverse regulation of CD95 ligand and receptor expression.
• CD95L-mediated killing of bystander cells by breast tumors may contribute to tissue invasion.
• The CD95 system represents a potential target for therapeutic intervention in breast cancer.